Evidence-based guideline for assessment, pharmacological management, interventional approaches, and supportive care of cancer-related pain.
A comprehensive, evidence-based clinical guideline for the assessment, classification, pharmacological and non-pharmacological management, interventional treatment, and supportive care of pain in patients with cancer and cancer survivors. This document synthesizes recommendations from multiple international professional societies and expert panels in oncology, palliative care, pain medicine, and anesthesiology to provide a single, authoritative reference for clinicians managing cancer-related pain across the disease trajectory.
Pain is one of the most feared and prevalent symptoms experienced by patients with cancer. Approximately 55% of patients undergoing active anticancer treatment and up to 66% of patients with advanced, metastatic, or terminal disease report clinically significant pain.1 Despite the availability of effective analgesic therapies, cancer pain remains undertreated in an estimated 30% to 50% of patients across all stages of disease, driven by barriers including inadequate pain assessment, clinician knowledge gaps regarding opioid pharmacology, regulatory concerns, and patient reluctance to report pain or take opioid medications.2 Furthermore, the growing population of cancer survivors — estimated at over 18 million individuals in the United States alone — faces a substantial burden of chronic pain, including treatment-related syndromes such as chemotherapy-induced peripheral neuropathy, post-surgical pain, and radiation-related sequelae.3
Effective cancer pain management requires a systematic approach that begins with thorough pain assessment, proceeds through multimodal pharmacological therapy guided by established frameworks such as the analgesic ladder, and incorporates interventional procedures, adjuvant analgesics, and non-pharmacological strategies as indicated. The goal is to achieve an acceptable balance between pain relief and functional capacity while minimizing adverse effects and addressing the psychological, social, and spiritual dimensions of the pain experience.4
This guideline is organized into five parts covering the complete spectrum of cancer pain assessment and management:
Contents:
| Part | Title | Coverage |
|---|---|---|
| Part 1 | Pain Assessment and Classification | Pain screening and assessment tools (NRS, VAS, Wong-Baker FACES, FLACC, BPI); comprehensive pain assessment components (OPQRSTUV); pain classification by mechanism (nociceptive somatic, nociceptive visceral, neuropathic, mixed); cancer-specific pain syndromes; bone metastasis pain; visceral pain syndromes; chemotherapy-induced neuropathy; radiation-associated pain |
| Part 2 | The Analgesic Ladder and Non-Opioid Pharmacotherapy | Updated three-step analgesic ladder with modern modifications; Step 1 non-opioid analgesics (acetaminophen, NSAIDs); Step 2 weak opioids (tramadol, codeine); NSAID selection in cancer patients with GI, renal, and cardiovascular considerations; adjuvant analgesic overview |
| Part 3 | Opioid Therapy: Selection, Titration, Rotation, and Adverse Effect Management | Opioid selection and initiation; complete equianalgesic dosing table; morphine, oxycodone, hydromorphone, fentanyl, and methadone dosing; titration protocols; extended-release formulations; breakthrough pain management; opioid rotation indications and methods; adverse effect prevention and treatment (constipation, nausea, sedation, respiratory depression, pruritus); methadone pharmacology and QTc considerations |
| Part 4 | Adjuvant Analgesics, Interventional Approaches, and CIPN Management | Anticonvulsants (gabapentin, pregabalin); antidepressants (duloxetine, TCAs); corticosteroids; bisphosphonates and denosumab; topical agents; nerve blocks; neuraxial drug delivery; palliative radiation therapy; radionuclides; vertebroplasty and kyphoplasty; chemotherapy-induced peripheral neuropathy prevention and treatment |
| Part 5 | Special Populations, Non-Pharmacological Approaches, Palliative Sedation, and Survivorship Pain | Elderly patients; pediatric considerations; renal and hepatic impairment; patients with substance use disorder history; palliative sedation for refractory pain; cognitive-behavioral therapy; physical and rehabilitation therapies; integrative medicine (acupuncture, massage, music therapy); survivorship chronic pain management |
Scope and Applicability: This guideline applies to all healthcare professionals involved in the assessment and management of pain in adult patients with active cancer, patients receiving anticancer therapy, and cancer survivors. It is relevant across care settings including inpatient oncology units, outpatient clinics, palliative care services, pain management clinics, home care, and hospice programs. Pediatric considerations are addressed in Part 5 with recognition that dedicated pediatric oncology pain guidelines should also be consulted for patients under 18 years of age.
Limitations: No guideline can anticipate all clinical situations. This document is not intended to replace individual clinical judgment by qualified professionals. Local institutional protocols, formulary availability, regulatory environments, and patient-specific factors must always be considered in clinical decision-making. Opioid dosing recommendations in this guideline assume opioid-naive patients unless otherwise specified; patients with existing opioid tolerance require individualized dosing adjustments.
van den Beuken-van Everdingen MHJ, Hochstenbach LMJ, Joosten EAJ, Tjan-Heijnen VCG, Janssen DJA. “Update on Prevalence of Pain in Patients With Cancer: Systematic Review and Meta-Analysis.” Journal of Pain and Symptom Management, 51(6): 1070–1090.e9, 2016. DOI: 10.1016/j.jpainsymman.2015.12.340 ↩︎
Deandrea S, Montanari M, Moja L, Apolone G. “Prevalence of Undertreatment in Cancer Pain: A Review of Published Literature.” Annals of Oncology, 19(12): 1985–1991, 2008. DOI: 10.1093/annonc/mdn419 ↩︎
Paice JA, Portenoy R, Lacchetti C, et al. “Management of Chronic Pain in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.” Journal of Clinical Oncology, 34(27): 3325–3345, 2016. Updated 2024. American Society of Clinical Oncology (ASCO). ↩︎
Fallon M, Giusti R, Aielli F, et al. “Management of Cancer Pain in Adult Patients: ESMO Clinical Practice Guidelines.” Annals of Oncology, 29(suppl 4): iv166–iv191, 2018. European Society for Medical Oncology (ESMO). DOI: 10.1093/annonc/mdy152 ↩︎
Pain management in elderly, pediatric, renal/hepatic impairment, and substance use disorder populations; non-pharmacological interventions; palliative sedation; and survivorship chronic pain strategies.
Adjuvant analgesic dosing for neuropathic and bone pain, interventional pain procedures, palliative radiation, and chemotherapy-induced peripheral neuropathy prevention and treatment.
Complete opioid pharmacotherapy for cancer pain including equianalgesic dosing, titration protocols, opioid rotation, breakthrough pain management, methadone pharmacology, and side effect treatment.
Updated WHO analgesic ladder framework, non-opioid analgesic selection and dosing, and weak opioid therapy for cancer pain management.
Comprehensive pain assessment tools, classification systems, and cancer-specific pain syndromes for systematic evaluation of pain in oncology patients.